|
Recent Developments |
|
11-FEB-19
Zydus Cadila has received the final approval from the USFDA to market Carbamazepine Extended-Release Tablets USP (US RLD - Tegretol XR), 100 mg, 200 mg, and 400 mg. It will be manufactured at the group???s formulations manufacturing facility at Moraiya, Ahmedabad.
21-JAN-19
Zydus Cadila has received the tentative approval from the USFDA to market Esomeprazole Magnesium Delayed-Release Capsules (US RLD-NEXIUM). It will be manufactured... More.. |
| Business Profile |
Future Plans |
|
| CEO Talk | | Cadila Healthcare Ltd, the homegrown pharma major that pioneered the concept of brand positioning in the Indian pharma market in the 1980s, is now poised for a new phase of export-led growth. Pankaj R Patel |
|
|
One To One
|
|
Recent news
|
|
|
| Period ending (months) | 31-Dec-2017(9) | 31-Mar-2017(12) | 31-Mar-2016(12) | | Net sales | 43675.00 | 42883.00 | 64365.20 | | Other Income | 1774.00 | 5844.00 | 1341.10 | | Total Income | 45449.00 | 48727.00 | 65706.30 | | Cost of goods sold | 32187.00 | 40345.00 | 44923.70 | | OPBDIT | 13262.00 | 8382.00 | 20782.60 | | PAT | 8476.00 | 7994.00 | 19773.30 | | Gross Block | - | - | - | | Equity capital | - | - | 1024.00 | | EPS (Rs.) | - | - | - | | DPS (Rs.) | - | - | - | | BV (Rs.) | - | - | - | | P/E range (x) | - | - | - | | Debt / Equity (x) | - | - | - | | Operating margin (% of OI) | 29.2 | 17.2 | 31.6 | | Net margin (% of OI) | 18.6 | 16.4 | 30.1 |
|
|
Detailed Financials
|
|
|
|
|
